zoledronic acid has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, S; Lin, Y; Lv, X; Song, C; Yu, Y; Zhang, J | 1 |
| Cheng, Y; Ji, Q; Liu, B; Liu, D; Liu, M; Yang, Q; Yang, Z; Zhang, B; Zhou, S | 1 |
| Jukkola, A; Määttä, J; Mattila, PK; Petruk, N; Sandholm, J; Selander, KS; Siddiqui, A; Tadayon, S | 1 |
| Clézardin, P; Croset, M; Määttä, J; Mönkkönen, J; Petruk, N; Polari, L; Selander, K; Sousa, S; Zlatev, H | 1 |
| Chen, CY; Chen, SC; Lin, TM; Liu, H; Wang, SH | 1 |
| Baretton, GB; Bauer, T; Benad-Mehner, P; Bornhäuser, M; Ebert, R; Göbel, A; Hadji, P; Hofbauer, LC; Jakob, F; Muders, MH; Rachner, TD; Rauner, M; Schem, C; Thiele, S | 1 |
| Akazawa, K; Hasegawa, Y; Hayashi, M; Horiguchi, J; Ishikawa, T; Kim, SJ; Kohno, N; Konishi, M; Kubota, T; Miura, D; Miyashita, M; Shigeoka, Y; Suzuki, M; Taguchi, T; Takao, S; Tanino, H; Yamagami, K | 1 |
| Amadori, D; Bongiovanni, A; De Vita, A; Ibrahim, T; Liverani, C; Mercatali, L; Miserocchi, G; Recine, F; Spadazzi, C | 1 |
1 review(s) available for zoledronic acid and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Efficacy and safety of neoadjuvant therapy for triple-negative breast cancer: a Bayesian network meta-analysis.
Topics: Albumin-Bound Paclitaxel; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; B7-H1 Antigen; Bayes Theorem; Bevacizumab; Humans; Ligands; Neoadjuvant Therapy; Network Meta-Analysis; Platinum; Programmed Cell Death 1 Receptor; Taxoids; Triple Negative Breast Neoplasms; Zoledronic Acid | 2022 |
1 trial(s) available for zoledronic acid and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diphosphonates; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Genes, erbB-2; Humans; Imidazoles; Middle Aged; Neoadjuvant Therapy; Treatment Outcome; Triple Negative Breast Neoplasms; Zoledronic Acid | 2015 |
6 other study(ies) available for zoledronic acid and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Calcium phosphate hybrid micelles inhibit orthotopic bone metastasis from triple negative breast cancer by simultaneously killing cancer cells and reprogramming the microenvironment of bone resorption and immunosuppression.
Topics: Bone Marrow Diseases; Bone Neoplasms; Calcium Phosphates; Cell Line, Tumor; Docetaxel; Humans; Immunosuppression Therapy; Micelles; Osteolysis; Triple Negative Breast Neoplasms; Tumor Microenvironment; Zoledronic Acid | 2023 |
CD73 regulates zoledronate-induced lymphocyte infiltration in triple-negative breast cancer tumors and lung metastases.
Topics: Animals; Humans; Imidazoles; Lung Neoplasms; Mice; Neoplasm Recurrence, Local; T-Lymphocytes; Triple Negative Breast Neoplasms; Zoledronic Acid | 2023 |
Liposome-encapsulated zoledronate increases inflammatory macrophage population in TNBC tumours.
Topics: Animals; Cell Line, Tumor; Diphosphonates; Female; Humans; Liposomes; Macrophages; Mice; Mice, Inbred BALB C; Triple Negative Breast Neoplasms; Zoledronic Acid | 2023 |
Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells.
Topics: Cell Communication; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CCL2; Chemokine CCL5; Female; Gene Expression Profiling; Humans; Immunologic Factors; Indoleamine-Pyrrole 2,3,-Dioxygenase; T-Lymphocytes, Regulatory; Triple Negative Breast Neoplasms; Tumor Microenvironment; Zoledronic Acid | 2019 |
Dickkopf-1 is regulated by the mevalonate pathway in breast cancer.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bone Density Conservation Agents; Bone Neoplasms; cdc42 GTP-Binding Protein; Cell Line, Tumor; Diphosphonates; Female; Gene Expression Regulation, Neoplastic; Heptanoic Acids; Humans; Imidazoles; Intercellular Signaling Peptides and Proteins; L Cells; Lymphocyte Activation; MCF-7 Cells; Mevalonic Acid; Mice; Osteoblasts; Osteogenesis; Osteoprotegerin; Prenylation; Pyrroles; Rho Factor; RNA Interference; RNA, Small Interfering; Triple Negative Breast Neoplasms; Wnt3A Protein; Zoledronic Acid | 2014 |
The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts.
Topics: Antineoplastic Agents; Biomarkers; Blotting, Western; Bone Neoplasms; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Denosumab; Diphosphonates; Everolimus; Gene Expression; Humans; Imidazoles; Intercellular Adhesion Molecule-1; Interleukin-6; MCF-7 Cells; Models, Biological; Osteoclasts; Osteonectin; RANK Ligand; Receptors, CXCR4; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factor beta; Triple Negative Breast Neoplasms; Zoledronic Acid | 2016 |